4-aminopyridine has been researched along with Lung Neoplasms in 16 studies
Lung Neoplasms: Tumors or cancer of the LUNG.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Mouse oral bioavailability was complete (100%) with extensive tumor exposure." | 1.43 | The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma. ( Aherne, GW; Box, G; Boxall, KJ; Collins, I; De Haven Brandon, AK; Eccles, SA; Eve, PD; Garrett, MD; Hayes, A; Henley, AT; Hunter, JE; Lainchbury, M; Matthews, TP; McHardy, T; Osborne, J; Perkins, ND; Raynaud, FI; Reader, JC; Swales, K; Tall, M; Valenti, MR; Walton, MI, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (50.00) | 18.2507 |
| 2000's | 6 (37.50) | 29.6817 |
| 2010's | 2 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Walton, MI | 1 |
| Eve, PD | 1 |
| Hayes, A | 1 |
| Henley, AT | 1 |
| Valenti, MR | 1 |
| De Haven Brandon, AK | 1 |
| Box, G | 1 |
| Boxall, KJ | 1 |
| Tall, M | 1 |
| Swales, K | 1 |
| Matthews, TP | 1 |
| McHardy, T | 1 |
| Lainchbury, M | 1 |
| Osborne, J | 1 |
| Hunter, JE | 1 |
| Perkins, ND | 1 |
| Aherne, GW | 1 |
| Reader, JC | 1 |
| Raynaud, FI | 1 |
| Eccles, SA | 1 |
| Collins, I | 1 |
| Garrett, MD | 1 |
| Uekita, K | 1 |
| Ishida, T | 1 |
| Sekine, S | 1 |
| Ishii, T | 1 |
| Sato, S | 1 |
| Sugawara, A | 1 |
| Tachihara, M | 1 |
| Watanabe, K | 1 |
| Kanazawa, K | 1 |
| Saito, J | 1 |
| Tanino, Y | 1 |
| Munakata, M | 1 |
| Titulaer, MJ | 2 |
| Lang, B | 1 |
| Verschuuren, JJ | 2 |
| Wang, L | 1 |
| Shao, G | 1 |
| Zhang, W | 1 |
| Guo, X | 1 |
| Wang, C | 1 |
| An, J | 1 |
| Zhong, G | 1 |
| Zhao, H | 1 |
| Newsom-Davis, J | 3 |
| Wirtz, PW | 1 |
| Willems, LN | 1 |
| van Gerven, J | 1 |
| Matsushima, M | 1 |
| Yaguchi, H | 1 |
| Kishimoto, R | 1 |
| Tsuji, S | 1 |
| Yabe, I | 1 |
| Sasaki, H | 1 |
| Nakadate, M | 1 |
| Shiraishi, H | 1 |
| Motomura, M | 1 |
| Morata, C | 1 |
| Alfaro, A | 1 |
| Chumillas, MJ | 1 |
| Montalar, J | 1 |
| Casanova, B | 1 |
| Vílchez, JJ | 1 |
| Rubio, P | 1 |
| Tim, RW | 2 |
| Massey, JM | 2 |
| Sanders, DB | 2 |
| Oh, SJ | 1 |
| Kim, DS | 1 |
| Kwon, KH | 1 |
| Tseng, A | 1 |
| Mussell, H | 1 |
| Claussen, GC | 1 |
| Seneviratne, U | 1 |
| de Silva, R | 1 |
| Chalk, CH | 1 |
| Murray, NM | 1 |
| O'Neill, JH | 1 |
| Spiro, SG | 1 |
| Manji, H | 1 |
| Schwartz, MS | 1 |
| McKeran, RO | 1 |
4 reviews available for 4-aminopyridine and Lung Neoplasms
| Article | Year |
|---|---|
Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies.
Topics: 4-Aminopyridine; Amifampridine; Autoantibodies; Calcium Channels; Carcinoma, Small Cell; Humans; Lam | 2011 |
Lambert-Eaton myasthenic syndrome.
Topics: 4-Aminopyridine; Amifampridine; Autoantibodies; Autoantigens; Autoimmune Diseases of the Nervous Sys | 2004 |
Available treatment options for the management of Lambert-Eaton myasthenic syndrome.
Topics: 4-Aminopyridine; Antineoplastic Agents; Carcinoma, Small Cell; Cholinesterase Inhibitors; Cisplatin; | 2006 |
Lambert-Eaton myasthenic syndrome.
Topics: 4-Aminopyridine; Amifampridine; Anti-Inflammatory Agents; Autoantibodies; Calcium Channels; Carcinom | 1999 |
12 other studies available for 4-aminopyridine and Lung Neoplasms
| Article | Year |
|---|---|
The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma.
Topics: 4-Aminopyridine; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; C | 2016 |
[A case of Lambert-Eaton myasthenic syndrome with small cell lung cancer, treated with 3,4-diaminopyridine].
Topics: 4-Aminopyridine; Aged; Amifampridine; Humans; Lambert-Eaton Myasthenic Syndrome; Lung Neoplasms; Mal | 2009 |
[Influence of 4-aminopyridine on voltage-activated K(+) current and cell proliferation in small cell lung cancer].
Topics: 4-Aminopyridine; Carcinoma, Small Cell; Cell Division; Humans; Lung Neoplasms; Potassium Channel Blo | 2002 |
[Successful treatment of a Lambert-Eaton myasthenic syndrome patient with 3,4-diaminopyridine].
Topics: 4-Aminopyridine; Amifampridine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposi | 2007 |
[Lambert-Eaton myasthenic syndrome: response to treatment with 3,4-diaminopyridine].
Topics: 4-Aminopyridine; Aged; Amifampridine; Carcinoma, Small Cell; Humans; Lambert-Eaton Myasthenic Syndro | 1995 |
[The treatment of the Eaton-Lambert myasthenic syndrome with 3,4-diaminopyridine].
Topics: 4-Aminopyridine; Amifampridine; Carcinoma, Small Cell; Drug Evaluation; Humans; Lambert-Eaton Myasth | 1993 |
A treatment algorithm for Lambert-Eaton myasthenic syndrome.
Topics: 4-Aminopyridine; Algorithms; Amifampridine; Azathioprine; Carcinoma, Small Cell; Clinical Protocols; | 1998 |
Lambert-Eaton myasthenic syndrome (LEMS). Clinical and electrodiagnostic features and response to therapy in 59 patients.
Topics: 4-Aminopyridine; Adolescent; Adult; Aged; Amifampridine; Autoantibodies; Carcinoma, Small Cell; Chil | 1998 |
Wide spectrum of symptomatic treatment in Lambert-Eaton myasthenic syndrome.
Topics: 4-Aminopyridine; Adult; Aged; Amifampridine; Carcinoma, Small Cell; Female; Guanidine; Humans; Lambe | 1998 |
Lambert-Eaton myasthenic syndrome: electrodiagnostic findings and response to treatment.
Topics: 4-Aminopyridine; Adolescent; Adult; Aged; Aged, 80 and over; Amifampridine; Carcinoma, Small Cell; C | 2000 |
Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma.
Topics: 4-Aminopyridine; Action Potentials; Adult; Aged; Amifampridine; Carcinoma, Small Cell; Combined Moda | 1990 |
Lambert Eaton syndrome: autonomic neuropathy and inappropriate antidiuretic hormone secretion in a patient with small cell carcinoma of the lung.
Topics: 4-Aminopyridine; Aged; Amifampridine; Carcinoma, Small Cell; Humans; Inappropriate ADH Syndrome; Lam | 1990 |